Feline aortic thromboembolism : prevention and novel acute management approaches by Evangelista González, Sara & Universitat Autònoma de Barcelona. Facultat de Veterinària
Acute thrombus resolution: not common practice
Thromboembolus interventionism
• Surgical thromboembolectomy: through aortotomy.
• Rheolytic thromboembolectomy: through percutaneous aspiration.
Systemic thrombolysis - Tissue Plasminogen Activator
→ Treatment of choice in humans with ATE.
→ Counted cases in cats, but successful.
→ Marginally superior to antithrombotic therapy.
→ Survival notably increases in high-dose protocols (77.8%).
→ Cost may preclude its use.
ACUTE MANAGEMENT
- CONCLUSIONS -
FELINE AORTIC THROMBOEMBOLISM: 
PREVENTION AND NOVEL ACUTE MANAGEMENT APPROACHES
Sara Evangelista González
Final Degree Project – June 2020
BACKGROUND
• ATE is more common in cats than any other species, comprising
79-85% of their arterial thromboembolism cases.
• Survival rates are low, ranging from 14-40% when there is a
bilateral pelvic limb infarction.
• CMs account for 90% of ATE cases, especially HCM.
• 5-21% of cats with HCM suffer from ATE.
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PREVENTION
1. Doppler echocardiography to define risk:
Moderate to severe LAD:
• LA:Ao > 1.9-2
• LA diameter > 17-20 mm
Blood flow velocities <0.20 m/s in
the LAA.
Spontaneous echocontrast (SEC) or
intracardiac thrombus
+/- Previous history of ATE
Figure: Right parasternal short-axis view of a cat with restrictive CM and severe LAD
and SEC (white arrows). LA (Left atrium); Ao (Aorta) (Chetboul et al. 2019) [Modified].
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2. Criteria for treatment application
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3. Thromboprophylactic treatment
ANTICOAGULANTS                +    ANTIPLATELET AGENTS 
OBJECTIVE
Postpone ATE 
onset or 
recurrence
CMs
Hyperthyroidism
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OR
LAD, SEC, low blood 
flow in the LAA
LMWHs (enoxaparin/dalteparin):
• Subcutaneous administration
NOACs (rivaroxaban/apixaban):
• Oral administration
• Requires further studies in cats
Reperfusion syndromeBlood flow 
resumption
Treatment must be attempted in
<4 hours since ATE onset
+
Adjuvant antithrombotic therapy
Clopidogrel:
• Oral administration
• Proved to reduce ATE 
recurrence and cardiac 
death.
 The detection of LAD, SEC and low blood flow velocities in the LAA can successfully predict ATE risk.
 The protocolisation of Doppler echocardiography in target patients and thromboprophylaxis prescription may significantly reduce ATE onset.
 Acute thrombus resolution techniques seem promising for cats with multiple limb infarction since they do not respond to antithrombotics.
 Early intervention of thrombus is crucial for survival, and its implementation in protocols could reduce euthanasia rates at presentation.
 Further studies are required to confirm the best multimodal thromboprophylactic therapy upon NOACs’ normalisation and to evaluate the
outcome of thrombus resolution techniques once refined and protocolised.
First cause 
of mortality
Severity
• Duration of ischaemia
• Extension of ischaemia
Abbreviations: ATE = aortic thromboembolism; CM = cardiomyopathy; HCM = hypertrophic
cardiomyopathy; LAD = left atrial dilation; LAA = left atrial appendage; LMWHs = low molecular
weight heparins; NOACs = new oral anticoagulants; UFHs = unfractionated heparins.
OBJECTIVES
• To perform a review on the state of the art of ATE’s acute
management and preventive approaches.
• Analyse the effectiveness of the current standard of care and the
available alternatives.
POOR PROGNOSIS
Hypothermia
Multiple affected limbs
Loss of motor function
• Induction of a hypocoagulable state: UFHs
prevents further embolus growth and microcirculation thrombosis.
• Improvement of collateral blood flow: clopidogrel (75 mg)
avoids the release of vasoactive substances.
Antithrombotic therapy: current standard of care
→ Sufficient in cats with a single limb infarcted.
→ Insufficient in cats with ≥ 2 limbs infarcted.
→ Euthanasia at presentation in 25-61% of patients.
→ Same risk of reperfusion syndrome as infarction resolution.
OUTCOME: survival rates of 31-45% in cats with arterial thromboembolism. 
